Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.
about
Investigation and Management of Adnexal Masses in PregnancyCurrent clinical application of serum biomarkers to detect ovarian cancerThe emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomasReply to comment of Prof. Artur CzekierdowskiPreoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC ConsortiumMALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancerLarge malignant ovarian tumors during pregnancy: two cases.Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese womenInterpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomasWAP four-disulfide core domain protein 2 gene(WFDC2) is a target of estrogen in ovarian cancer cellsAssessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic massCan ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?Management of gynecological cancers during pregnancy.A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes.Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies.Comparison of the Serum Level of Cancer Antigen 125 and Human Epididymis Protein 4 in Ovarian Cancer Patients and Healthy Groups in Isfahan City.Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer.Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors.Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women.Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?Comparison of HE4 and CA125 levels in women with benign gynecologic disorders : Does age or menopausal status matter?The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?Determination of the Reference Values of the Tumor Marker HE4 in Female Population of Canton Sarajevo.Current approaches in the clinical management of pregnancy-associated breast cancer-pros and cons
P2860
Q26749425-84E31024-94F4-409F-86FE-A4648149E007Q26768709-17E63C55-8ACC-41C7-AFC0-35EFF0447833Q26992102-B93E1BE1-F967-40CA-A1E4-5F0F0583BF6AQ30355814-4AFC9F60-4C20-45BB-8B7E-E7E93BF31F41Q33624809-F5C07BF0-ADB9-4E26-9BFD-D6D09D1C5974Q33883474-9EA31BCD-4D65-429D-A0AE-90E8B38222CEQ34555396-DFCF9A2A-0FA2-4A4A-9AC6-1011A79C0CC7Q34675023-C9A19B7B-46C5-4BEC-A33C-254E46416FA7Q36262845-928675E7-533D-4F79-BA6C-EF32A86E0D8DQ36385490-656D06CF-B5EE-46CE-85EF-564C0CD947C7Q36400522-8DC84086-0C37-4024-B4E3-8F0459315405Q36565979-DE2D0A62-40FB-42E0-9760-735675776AD6Q36629304-E42B066C-B565-44AB-83F7-8854C6E037D0Q36904090-97F769D2-5B30-4E75-8922-1742F7B636B5Q37188163-BC0345A6-D091-4AD1-B176-5403E2067441Q38262618-0DB00B93-BB75-469E-8927-9F849D6E37B5Q38602857-A9DFFC54-C5F8-41A3-87DA-E43C0AB55C5FQ38819035-37064741-A13C-4997-8142-96590009C361Q38991579-A21C6E73-01D9-4BA7-8712-B8746B28A795Q47124965-2EF6F31A-6976-47BD-BB30-4F5AACB684FEQ47134921-C3B3F958-6634-4EE3-AFF3-0C4D11DFB9EBQ47230018-9A627E11-B01B-4B16-B6CD-D0144D150BC8Q47342066-ED9C0A31-B133-42ED-85C5-B5EFDA77A51AQ47605672-555517AD-6B79-4994-A7BE-5602458965CAQ50857141-0EDC2F00-A0BA-4506-A7F5-8A9079699630Q51382154-D8C52A00-A2BD-4DD4-8E74-F5DD06B93603Q51435881-CAE0DB04-AFF9-44E2-B0DF-34C47DD21961Q55280402-2EFC12C0-115F-4720-9D5C-A9EEDA4C0C6FQ55400446-82C9DC28-69DE-4560-99F1-1E98AA4E01B0Q57111028-2AA21759-06E7-4B42-8AA2-EEF4AC90E813
P2860
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 December 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serum levels of the ovarian ca ...... egnancy and increase with age.
@en
Serum levels of the ovarian ca ...... egnancy and increase with age.
@nl
type
label
Serum levels of the ovarian ca ...... egnancy and increase with age.
@en
Serum levels of the ovarian ca ...... egnancy and increase with age.
@nl
prefLabel
Serum levels of the ovarian ca ...... egnancy and increase with age.
@en
Serum levels of the ovarian ca ...... egnancy and increase with age.
@nl
P2093
P2860
P1476
Serum levels of the ovarian ca ...... egnancy and increase with age.
@en
P2093
Elizabeth E Eklund
Geralyn Lambert-Messerlian
Karen H Lu
Michael Craig Miller
Richard G Moore
P2860
P304
P356
10.1016/J.AJOG.2011.12.028
P407
P577
2011-12-30T00:00:00Z